Preimplantation Genetic Testing Market To Reflect Impressive Growth Rate By 2024: Grand View Research, Inc.

Posted on 2018-11-28 by researchinsights in Biotech, Healthcare // 0 Comments

San Francisco, United States, 2018-Nov-28 — /EPR Network/ —The global preimplantation genetic testing market size is projected to amount to a value of USD 221.1 million by 2024, according to a new report by Grand View Research, Inc. The market is primarily driven by an increase in number of offspring born with inherited medical conditions. Thanks to the emergence of preimplantation genetic testing (PGT) and diagnosis to detect nearly all genetically inherited conditions, couples who are carriers of such conditions can screen their embryos at an earlier stage.

Rising adoption of IVF, resulting from an increase in incidence of pregnancy-related complications, is projected to boost demand for preimplantation genetic testing services. Women undergoing IVF are expected to undergo PGT cycles in order to prevent the transfer of chromosomal abnormalities to their offspring.

Increasing demand for these tests can also be attributed to rising infertility rate around the world. This has been brought on by various environmental and lifestyle factors, eventually driving the need for PGT services.

To request a sample copy or view summary of this report:
www.grandviewresearch.com/industry-analysis/preimplantation-genetic-testing-pgt-market

Further key findings from the study suggest:

Preimplantation genetic testing is available for different types of services, which include X-linked diseases, Human Leukocyte Antigen (HLA) typing, chromosomal abnormalities, freeze embryo testing, aneuploidy screening, detection of serious late-onset diseases, and gender selection. Preimplantation genetic testing for chromosomal abnormalities accounted for approximately 29% of the market share due to advancements in its screening by the use of noninvasive prenatal testing, which employs cell-free DNA for early detection of chromosomal abnormalities, such as Patau syndrome, Edwards syndrome, and Down syndrome.
This technology has various applications. Amongst all the applications, embryo HLA typing for stem cell therapy dominated with a share of over 30%. This largest share can be attributed to the benefits associated with the use of PGD for identification of HLA compatible embryos for stem cell therapy.
Although usage of these tests for inherited chromosomal disease is observed to have less penetration in the current scenario, it is expected to witness tremendous growth in the coming years due to increasing adoption rate of this service for detection of inherited genomic anomalies, such as sickle cell anemia and Huntington’s disease.
Europe accounted for the largest share with respect to revenue as a result of growing awareness about the scope of these diagnostic services for delivering genetically fit offspring. Also, developed infrastructure, rising investments by governmental bodies, and presence of key players in this region, collectively encourages growth of this industry in this region.
Some of the key players that have commercialized PGT services include F. Hoffmann-La Roche AG; Genea Limited; Quest Diagnostics, Illumina, Inc.; Natera, Inc; CooperSurgical, Inc; LabCorp; California Pacific Medical Center; Thermo Fisher Scientific, Inc; Igenomix; Reproductive Genetic Innovations, LLC; CombiMatrix; Good Start Genetics, Inc; Bioarray S.L; and Reproductive Health Science Ltd.
These key participants are actively involved in the R&D initiatives for development of novel PGT services. Partnership between entities and acquisition of small companies by major companies in order to reinforce its status in the market as well as to expand its product catalog for this vertical is expected boost revenue generation in preimplantation genetic diagnostics.
For instance, In December 2015, Natera, entered into a partnership with MedGenome, provider of genomic solutions for personalized healthcare in India. As per this partnership, MedGenome will be allowed to use the Panorama noninvasive prenatal test in its research laboratory. As a result, MedGenome becomes the first provider of this service in India.

Related Report of Biotechnology:

Grand View Research has segmented preimplantation genetic testing market on the basis of application, type, and region:

Type Outlook (Market Revenue in USD Million, 2013 – 2024)

Chromosomal Abnormalities
X-linked Diseases
Freeze Embryo Testing
Aneuploidy Screening
HLA Typing
Other PGT Types

Application Outlook (Revenue in USD Million, 2013 – 2024)

Embryo HLA Typing for Stem Cell Therapy
IVF Prognosis
Late-Onset Genetic Disorders
Inherited Genetic Disease
Others

Regional Outlook (Market Revenue in USD Million, 2013 – 2025)

North America
- U.S.
- Canada
Europe
- Germany
- UK
Asia Pacific
- Japan
- China
Latin America
- Brazil
- Mexico
Middle East and Africa
- South Africa

Access Press Release Of This Research Report by Grand View Research: www.grandviewresearch.com/press-release/global-preimplantation-genetic-testing-pgt-market

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Matched content

Editor’s pick